drugset
drugset / Trial / NCT04974216

Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

NCT04974216 ↗

Phase 2 Active not recruiting 71 enrolled The Lymphoma Academic Research Organisation
NaSingle-groupOpen-labelTreatment

Summary

This study evaluate the efficacy of Tafasitamab and Lenalinomide associated to Rituximab in elderly patients with frontline Diffuse Large B-Cell Lymphoma as assessed by the Overall Response Rate (ORR) after 3 cycles of treatment according to Lugano Response Criteria.

Timeline

Start
2021-12-20
Primary completion
2024-07-15
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 15 mg Oral
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Tafasitamab Monoclonal antibody 12 mg/kg Intravenous

Indications

diffuse large B-cell lymphoma